Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Capital Expenditures (2016 - 2026)

Pharma-Bio Serv's Capital Expenditures history spans 17 years, with the latest figure at $2411.0 for Q1 2026.

  • For Q1 2026, Capital Expenditures changed N/A year-over-year to $2411.0; the TTM value through Jan 2026 reached $9055.0, down 94.3%, while the annual FY2025 figure was $6644.0, 95.84% down from the prior year.
  • Capital Expenditures reached $2411.0 in Q1 2026 per PBSV's latest filing, up from $350.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $157015.0 in Q4 2024 to a low of -$1580.0 in Q4 2023.
  • Average Capital Expenditures over 5 years is $13951.3, with a median of $2061.5 recorded in 2022.
  • Peak YoY movement for Capital Expenditures: plummeted 113.02% in 2023, then soared 10037.66% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $12137.0 in 2022, then crashed by 113.02% to -$1580.0 in 2023, then skyrocketed by 10037.66% to $157015.0 in 2024, then tumbled by 99.78% to $350.0 in 2025, then skyrocketed by 588.86% to $2411.0 in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Capital Expenditures are $2411.0 (Q1 2026), $350.0 (Q4 2025), and $2036.0 (Q3 2025).